Petitioner Must Show Actual Injury to Establish Standing to Appeal PTAB Final Written Decision

Jan 17, 2017

Reading Time : 2 min

Phigenix, the party seeking judicial review, bears the burden to establish standing.  To prove standing, Phigenix must establish that (1) it suffered an injury in fact, (2) the injury is fairly traceable to challenged conduct of ImmunoGen, and (3) the injury is likely to be redressed by a favorable judicial outcome. First, the Federal Circuit addressed threshold issues of the burden of production, evidence to meet that burden, and when the evidence must be produced in cases where the appellant seeks review of final agency actions and its standing is challenged. The appellant’s burden of production is the same as a plaintiff moving for summary judgment in district court. An appellant is permitted to supplement the administrative record with arguments, affidavits or other evidence to demonstrate its standing, if the appellant’s standing is not self-evident (i.e., the appellant is not “an object of the action (or forgone action) at issue.”). Sierra Club v. EPA, 292 F.3d 895, 900 (D.C. Cir. 2002) (quoting Lujan v. Defs. Of Wildlife, 504 U.S. 555, 561-62 (1992)). Finally, if there is no evidence on the record to support standing, the appellant must provide evidence establishing its standing at the earliest possible opportunity because standing involves threshold questions over the court’s authority to hear the dispute.  

The Federal Circuit held that Phigenix did not have standing to appeal the PTAB decision in federal court because it failed to establish that it suffered an injury. Phigenix asserted that although it does not face the risk of infringing the ’856 patent, it has suffered actual economic injury because the ’856 patent increases competition between Phigenix and ImmunoGen for licensing revenue. The Federal Circuit held that the documents and declarations Phigenix relied on to support its claim are insufficient to show injury in fact because they are merely a conclusory statement about a hypothetical licensing injury and do not establish that Phigenix ever licensed the ’534 patent to anyone, let alone to entities that obtained licenses to ImmunoGen’s ’856 patent. Phigenix’s remaining arguments that it suffered an injury based on the estoppel effect of the PTAB’s decision and the violation of its procedural right to seek an appeal under 35 U.S.C. § 141 (c) were also denied. Thus, Phigenix’s appeal of the PTAB’s decision was dismissed.

Phigenix, Inc. v. ImmunoGen, Inc., No. 2016-1544 (Fed. Cir. Jan. 9, 2017).   

Share This Insight

Previous Entries

IP Newsflash

August 29, 2025

In a recent order addressing four IPR proceedings, the PTAB exercised its inherent authority under 37 C.F.R. § 42.5(a) to sua sponte authorize post-hearing discovery on a potentially dispositive privity issue. The order followed a Director review decision that vacated and remanded earlier IPRs involving the same parties, patent family, and privity issue. 

...

Read More

IP Newsflash

August 29, 2025

The Patent Trial and Appeal Board denied institution of an inter partes review petition in part because it determined that a patent reference was not prior art under the common ownership exception of pre-AIA 35 U.S.C. § 103(c)(1).

...

Read More

IP Newsflash

August 11, 2025

In considering a motion to dismiss infringement claims for two related patents, the District of Massachusetts recently held that pre-suit knowledge of a “parent” patent, without more, is insufficient to establish pre-suit knowledge of the “child” patent for purposes of indirect and willful infringement.

...

Read More

IP Newsflash

August 8, 2025

Following a jury verdict finding trade secret misappropriation, the District Court for the District of Massachusetts granted-in-part a plaintiff’s motion for a permanent injunction to prohibit defendants from using plaintiff’s trade secrets. The district court further required defendants to reassign to plaintiff patents and patent applications that disclosed or were derived from plaintiff’s trade secrets as part of its equitable relief.

...

Read More

IP Newsflash

August 6, 2025

In ruling on a recent motion to strike, a judge in the Eastern District of Texas permitted a damages expert to rely on a damages theory based on defendant’s “avoided costs,” holding that this theory did not run afoul of the “entire market value rule.”

...

Read More

IP Newsflash

August 5, 2025

The Federal Circuit recently vacated a decision by the Patent Trial and Appeal Board after concluding that the board’s analysis of licensing evidence offered as a secondary consideration of nonobviousness constituted legal error and was not supported by substantial evidence. According to the court, the board applied a more exacting and improperly heightened nexus standard than is required by law for license evidence.

...

Read More

IP Newsflash

August 5, 2025

A Northern District of California judge recently granted a motion to reconsider his summary judgment ruling that defendant was barred from raising certain “device art” due to IPR estoppel under 35 U.S.C. § 315(e)(2). In the original ruling, the judge adopted the broader rule that IPR estoppel applies to device art that is “materially identical” to patents or printed publications that petitioners raised, or could have raised, in an IPR. Following that ruling, however, the Federal Circuit issued its Ingenico decision adopting the narrower view that IPR estoppel applies only to “grounds” based on patents and printed publications and not to device-based grounds. Citing Ingenico as a “change of law,” defendant moved for reconsideration of the court’s ruling, and the court granted the motion.

...

Read More

IP Newsflash

August 5, 2025

In a recent decision designated as Informative, the USPTO Director determined that the Patent Trial and Appeal Board abused its discretion by instituting two inter partes review proceedings challenging the same patent, based on petitions advancing different constructions of the same claim term. The Director expressed concerns that permitting multiple petitions based on alternative claim constructions effectively circumvents word count limitations, strains board resources, and undermines procedural efficiency.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.